TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11809123

Group type: EXPERIMENTAL
Intervention: nabumetone (1000 mg/day)
Number of subjects: 125

Group type: COMPARATOR
Intervention: diclofenac sodium (75 mg/day)
Number of subjects: 125
Study: 9662321

Group type: EXPERIMENTAL
Intervention: Modified biophysical profile plus evaluation of the middle cerebral artery to umbilical artery systolic/diastolic ratio (Group 2)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Modified biophysical profile (Group 1)
Number of subjects: 665
Study: 7819846

Group type: EXPERIMENTAL
Intervention: Midwives unit
Number of subjects: 2844
Study: 3043571

Group type: EXPERIMENTAL
Intervention: 40 ml prilocaine 1.5%
Number of subjects: 100

Group type: COMPARATOR
Intervention: 40 ml bupivacaine 0.375%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 ml prilocaine 1% + 20 ml bupivacaine 0.5%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 ml prilocaine 2% + 20 ml bupivacaine 0.5%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 ml prilocaine 2% + 20 ml bupivacaine 0.375%
Number of subjects: 100
Study: 31191103

Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration (80 Hz) for 30 s
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration (80 Hz) for 300 s
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive control condition (300 s)
Number of subjects: 11
Study: 29033547

Group type: EXPERIMENTAL
Intervention: Tablet formulation of tacrolimus
Number of subjects: 47
Study: 24812287

Group type: EXPERIMENTAL
Intervention: Multi-biomarker disease activity (MBDA) score
Number of subjects: 235

Group type: COMPARATOR
Intervention: Low and moderate MBDA scores
Number of subjects: 235

Group type: COMPARATOR
Intervention: Low/moderate CRP, moderate DAS28-CRP, moderate DAS28-ESR
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: MBDA score as a continuous variable
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: MBDA score as a dichotomised variable (high vs low/moderate)
Number of subjects: 235
Study: 23324897

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21798637

Group type: EXPERIMENTAL
Intervention: Double-bundle reconstruction
Number of subjects: 22

Group type: COMPARATOR
Intervention: Single-bundle reconstruction
Number of subjects: 22
Study: 18440058

Group type: EXPERIMENTAL
Intervention: Group transit training only
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Group transit training and free bus pass
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no training or bus pass)
Number of subjects: 41
Study: 17152732

Group type: EXPERIMENTAL
Intervention: Mildronate 500 mg/day
Number of subjects: 117

Group type: COMPARATOR
Intervention: Traditional basal therapy
Number of subjects: 117
Study: 14747052

Group type: EXPERIMENTAL
Intervention: Second-line hormonal therapy using ketoconazole and hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel and estramustine combination chemotherapy
Number of subjects: 0
Study: 10694774

Group type: EXPERIMENTAL
Intervention: Oleic acid enriched diet (olive oil)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MUFA diet enriched in sunflower oil
Number of subjects: 22

Group type: COMPARATOR
Intervention: NCEP‐I diet
Number of subjects: 22
Study: 9351755

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 200 microg every 3 hours for a maximum of five doses in the first 24 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral misoprostol 200 microg every 3 hours for a maximum of five doses in the first 24 hours
Number of subjects: 0
Study: 8475960

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 208

Group type: COMPARATOR
Intervention: Intermittent pneumatic calf compression
Number of subjects: 208
Study: 3549601

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31994364

Group type: EXPERIMENTAL
Intervention: 10 mL/kg/h rate 5% Dextrose infusion preoperatively for 30 minutes, followed by Ringer's lactate until the end of surgery
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 10 mL/kg/h rate of Ringer's lactate preoperatively for 30 minutes, followed by 5% Dextrose during the operation
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ringer's lactate solution infusion at a rate of 10 mL/kg/h preoperatively and intraoperatively
Number of subjects: 93
Study: 29522076

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir (SOF/VEL) with Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir (SOF/VEL) with other ARV regimens (ATV, COBI, DRV, DTG, EVG, FTC, LPV, RAL, RPV, RTV, TAF, TDF)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir (SOF/VEL) with TDF-containing regimens
Number of subjects: 237
Study: 27004290

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel plus bovine-derived xenograft
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bovine-derived xenograft without PRP gel
Number of subjects: 16
Study: 24135845

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (AMP) 10 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (AMP) 20 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23494549

Group type: EXPERIMENTAL
Intervention: Tai Chi practitioners
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study: 20726448

Group type: EXPERIMENTAL
Intervention: Peer review intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17996409

Group type: EXPERIMENTAL
Intervention: Immediate release formulation of metformin hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended release formulation of metformin hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hexadecane membrane (HDM) system
Number of subjects: 0
Study: 15714177

Group type: COMPARATOR
Intervention: Calcium (400 mg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Calcium (400 mg daily) + Vitamin D3 (25,000 IU monthly)
Number of subjects: 90
Study: 12890859

Group type: EXPERIMENTAL
Intervention: Acupuncture with electrical stimulation biweekly for 5 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (usual care: NSAIDs, muscle relaxants, paracetamol, back exercises)
Number of subjects: 55
Study: 11050579

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/day
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 9113805

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 1286720

Group type: EXPERIMENTAL
Intervention: Sezolamide 1.8% added to timolol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Timolol and placebo
Number of subjects: 36
Study: 4059297

Group type: EXPERIMENTAL
Intervention: triletide (1.5 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: antacids (0.8 g/day each of aluminium hydroxide and magnesium hydroxide)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: triletide (1.5 g/day) in combination with antacids
Number of subjects: 30
Study: 31746742

Group type: EXPERIMENTAL
Intervention: Prolonged occlusion flow‐mediated dilatation (PO‐FMD)
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Sham PO‐FMD
Number of subjects: 1156
Study: 28718728

Group type: EXPERIMENTAL
Intervention: Clofarabine (CIA) 15 mg/m2
Number of subjects: 81

Group type: COMPARATOR
Intervention: Fludarabine (FIA)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Clofarabine (CIA)
Number of subjects: 81
Study: 27112311

Group type: EXPERIMENTAL
Intervention: Microenema with phenobarbital tablets crushed and suspended in 20 mL of tap water (MC-20)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microenema with phenobarbital tablets crushed and suspended in 6 mL of tap water (MC-6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suppository
Number of subjects: 0
Study: 24759125

Group type: EXPERIMENTAL
Intervention: Structured intensive management with protocol adherence scores of 1-5
Number of subjects: 1562

Group type: EXPERIMENTAL
Intervention: Highest protocol adherence (n=270, 26%)
Number of subjects: 1562

Group type: EXPERIMENTAL
Intervention: Least protocol adherence (n=148, 14%)
Number of subjects: 1562

Group type: EXPERIMENTAL
Intervention: Clinics equipped with a practice nurse
Number of subjects: 1562

Group type: EXPERIMENTAL
Intervention: Overall protocol adherence
Number of subjects: 1562
Study: 21805307

Group type: EXPERIMENTAL
Intervention: Prebiotic (mannanoligosaccharide) 4 g/calf/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no prebiotic supplementation)
Number of subjects: 36
Study: 20080837

Group type: EXPERIMENTAL
Intervention: Diiodothyropropionic acid (DITPA) at escalating doses (90 to 180, 270, and 360 mg/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 18031820

Group type: EXPERIMENTAL
Intervention: Artisan/Verisyse phakic intraocular lens implantation
Number of subjects: 684
Study: 11431853

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9402779

Group type: EXPERIMENTAL
Intervention: Two hour training programme for general practice reception staff
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 2064

Group type: EXPERIMENTAL
Intervention: Two hour training programme for general practice reception staff (specifically for Indian women)
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Control group (no training, specifically for Indian women)
Number of subjects: 2064
Study: 8417049

Group type: EXPERIMENTAL
Intervention: Direct current ablation (20 patients) using up to four shocks of 200 to 300 J
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (20 patients) using up to 15 applications of 16 to 25 W for 30 s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Direct current ablation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direct current ablation and Radiofrequency ablation
Number of subjects: 40
Study: 3323457

Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 288

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 288
Study: 30047258

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for 48 weeks
Number of subjects: 209
Study: 27225602

Group type: EXPERIMENTAL
Intervention: Treadmill exercise program (walking on a treadmill with fixed 0% grade, 3 times weekly for 48 weeks, first 12 weeks supervised, remaining 36 weeks unsupervised)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (encouraged to walk twice a week for 45 minutes and received standard health recommendations)
Number of subjects: 80
Study: 25577164

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide/50% oxygen
Number of subjects: 20

Group type: COMPARATOR
Intervention: 50% nitrogen/50% oxygen (placebo control)
Number of subjects: 20
Study: 23511244

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 19756774

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg PO, ondansetron 32 mg IV, dexamethasone 12 mg day 1; aprepitant 80 mg days 2-3; dexamethasone 8 mg qd days 2-4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (ondansetron 32 mg IV, dexamethasone 20 mg PO day 1; dexamethasone 8 mg bid days 2-4)
Number of subjects: 0
Study: 18982408

Group type: EXPERIMENTAL
Intervention: ROSE Program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 36
Study: 16640521

Group type: EXPERIMENTAL
Intervention: Portal vein flush with 500 cm(3) of Ringer's lactate without vena caval venting (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vena caval venting with no portal vein flush (Group B)
Number of subjects: 50
Study: 12631089

Group type: EXPERIMENTAL
Intervention: 1 g vitamin C
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 2 g vitamin C
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 1 g vitamin C (healthy subjects)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (15 subjects with EDTA)
Number of subjects: 47
Study: 10973867

Group type: EXPERIMENTAL
Intervention: Oral salbutamol (five doses of 4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (two doses of 100 microgram)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum dosage of inhaled salbutamol (1600 microgram in 24 h, 800 microgram in the last 4 h)
Number of subjects: 0
Study: 8836892

Group type: EXPERIMENTAL
Intervention: Recombinant IFN alpha 3 MU three times a week for 12 months
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid IFN alpha 3 or 5 MU three times a week for 6 or 12 months (total dosage 216‐720 MU)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Genotype 1
Number of subjects: 81

Group type: COMPARATOR
Intervention: Genotype 2
Number of subjects: 81

Group type: COMPARATOR
Intervention: Genotype 3
Number of subjects: 81

Group type: COMPARATOR
Intervention: Type 2 and 3 infections
Number of subjects: 81
Study: 1592888

Group type: EXPERIMENTAL
Intervention: Metyrapone (30 mg/kg body weight) administered at midnight
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31928568

Group type: EXPERIMENTAL
Intervention: Therapist-guided ICBT
Number of subjects: 255

Group type: COMPARATOR
Intervention: Self-guided ICBT
Number of subjects: 255
Study: 30541009

Group type: EXPERIMENTAL
Intervention: Lidcombe Program
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Integrated (Lid-PCIT) Program
Number of subjects: 6
Study: 28193231

Group type: EXPERIMENTAL
Intervention: High OPN mRNA expression
Number of subjects: 975

Group type: COMPARATOR
Intervention: Low OPN mRNA expression
Number of subjects: 975
Study: 27255641

Group type: EXPERIMENTAL
Intervention: Allergic group (n=30)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Non-allergic group (n=81)
Number of subjects: 321
Study: 24405903

Group type: EXPERIMENTAL
Intervention: Standard stimuli (SS) during passive auditory stimulation (PAS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Deviant stimuli (DS) during passive auditory stimulation (PAS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal controls (C)
Number of subjects: 32
Study: 22854557

Group type: EXPERIMENTAL
Intervention: Syringe group
Number of subjects: 145

Group type: COMPARATOR
Intervention: Vacuum tube group
Number of subjects: 145
Study: 19489488

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Quchi (LI 11)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine Nicardipine
Number of subjects: 60
Study: 18681090

Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg via single-dose dry powder inhaler (SDDPI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Indacaterol 200 microg via multidose dry powder inhaler (MDDPI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 15647223

Group type: EXPERIMENTAL
Intervention: Comparative randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision-modeling approaches
Number of subjects: 0
Study: 14506028

Group type: EXPERIMENTAL
Intervention: High-dose azithromycin (20 mg/kg once a day for 3 days)
Number of subjects: 304

Group type: COMPARATOR
Intervention: High-dose amoxicillin-clavulanate (90 mg/kg divided twice a day for 10 days)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: High-dose azithromycin
Number of subjects: 304

Group type: COMPARATOR
Intervention: High-dose amoxicillin-clavulanate
Number of subjects: 304
Study: 10692928

Group type: EXPERIMENTAL
Intervention: New two-stage technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Scalpel blade without micro-homogenisation
Number of subjects: 24
Study: 8678516

Group type: EXPERIMENTAL
Intervention: Leucovorin (LV, 30 mg/body) + 5‐fluorouracil (5‐FU 500 ‐ 750 mg/body) administered intravenously
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Leucovorin (LV, 30 mg/body) + 5‐fluorouracil (5‐FU 500 ‐ 750 mg/body) administered via intra‐hepatic artery injection
Number of subjects: 17
Study: 1954529

Group type: EXPERIMENTAL
Intervention: Videofluoroscopy assessment of swallowing
Number of subjects: 24
Study: 6344590

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31880795

Group type: EXPERIMENTAL
Intervention: Genetic Risk Score (GRS) based on 110 known PCa risk-associated SNPs, classified into low (<0.50), average (0.50-1.49), and high (≥1.50) risk groups.
Number of subjects: 3225

Group type: EXPERIMENTAL
Intervention: Combination of GRS and family history (FH)
Number of subjects: 3225

Group type: COMPARATOR
Intervention: Family History (FH)
Number of subjects: 3225
Study: 28958691

Group type: EXPERIMENTAL
Intervention: Hypocaloric diets reduced in either carbohydrates or fat
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Changes in 3-HIB
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 3-HIB
Number of subjects: 109
Study: 25799001

Group type: EXPERIMENTAL
Intervention: WhatsApp chat room-based competition for oral hygiene compliance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard oral hygiene instructions without app)
Number of subjects: 80
Study: 25050986

Group type: EXPERIMENTAL
Intervention: Lactate minimum intensity (LM)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Critical speed (CS)
Number of subjects: 46
Study: 21748825

Group type: EXPERIMENTAL
Intervention: Somatosensory stimulation of two nerves (ulnar and median)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Somatosensory stimulation of three nerves (ulnar, median, and radial)
Number of subjects: 10
Study: 19279226

Group type: EXPERIMENTAL
Intervention: Methylprednisolone plus lidocaine (steroid)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline plus lidocaine (saline)
Number of subjects: 58
Study: 17559628

Group type: EXPERIMENTAL
Intervention: Experimental gingivitis (initial prophylaxis followed by total neglect of oral hygiene)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Persistent gingivitis (continued habitual insufficient oral hygiene)
Number of subjects: 26
Study: 15159285

Group type: EXPERIMENTAL
Intervention: Prednisolone 20 mg/day for three months, with tapering dose in month 4, plus multidrug treatment
Number of subjects: 636

Group type: COMPARATOR
Intervention: Multidrug treatment alone
Number of subjects: 636
Study: 11477464

Group type: EXPERIMENTAL
Intervention: Biscuit with synthetic beta-carotene (SB)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Biscuit with red palm oil (PB)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo biscuit
Number of subjects: 400
Study: 9736815

Group type: COMPARATOR
Intervention: Patients without diabetic retinopathy (n=122)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: All patients (n=221)
Number of subjects: 221
Study: 8053433

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 2502091

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 78

Group type: COMPARATOR
Intervention: No thrombolysis
Number of subjects: 78
Study: 29561654

Group type: EXPERIMENTAL
Intervention: Customized nickel titanium (NiTi) archwires
Number of subjects: 32

Group type: COMPARATOR
Intervention: Preformed heat‐activated archwires
Number of subjects: 32
Study: 28249684

Group type: EXPERIMENTAL
Intervention: ETT + MR (group 1)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ETT without MR (group 2)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: LMA with subparalytic dose of MR (group 3)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: LMA without MR (group 4)
Number of subjects: 78
Study: 25403334

Group type: EXPERIMENTAL
Intervention: Rhodiola crenulata 500 mg daily for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (starch/phosphate buffered saline) daily for 12 weeks
Number of subjects: 38
Study: 23715475

Group type: EXPERIMENTAL
Intervention: Yoga intervention for 6 months in addition to hospital routine care
Number of subjects: 75

Group type: COMPARATOR
Intervention: Hospital routine care only
Number of subjects: 75
Study: 21241369

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) measurements of hair shafts from alopecic area
Number of subjects: 9

Group type: COMPARATOR
Intervention: Optical coherence tomography (OCT) measurements of hair shafts from unaffected area
Number of subjects: 9
Study: 18081753

Group type: EXPERIMENTAL
Intervention: Dapsone + desloratadine (10 mg daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Desloratadine (10 mg daily)
Number of subjects: 65
Study: 16987381

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional CRT indication (control group)
Number of subjects: 15
Study: 12589118

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 104
Study: 10553740

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 8920847

Group type: EXPERIMENTAL
Intervention: Haptic estimates
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Visual estimates
Number of subjects: 72

Group type: COMPARATOR
Intervention: Knowledge of estimate type
Number of subjects: 72
Study: 1862893

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with fentanyl 0.0002%
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.062% with fentanyl 0.0002%
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.031% with fentanyl 0.0002%
Number of subjects: 56

Group type: COMPARATOR
Intervention: bupivacaine 0.5% 8 ml initial dose with fentanyl 0.0002%
Number of subjects: 56